Photocure ASA

Regulatory Filings • Oct 5, 2020

Photocure announces new Cevira patent in Europe

Photocure announces new Cevira patent in Europe

Oslo, Norway, 5 October 2020: Photocure ASA (OSE:PHO) today announces that the

European Patent Office (EPO) has granted patent EP 2983780 covering the

commercial Cevira[®] device in Europe until 2034.

Cevira is a photodynamic drug-device combination product under development for

non-surgical treatment of high-grade cervical dysplasia. In July 2019, Photocure

announced that it had entered into a License Agreement providing Asieris

Meditech Co., Ltd (Asieris) with a world-wide license to develop and

commercialize Cevira for the treatment of HPV induced cervical precancerous

lesions. In July 2020, Asieris received China NMPA's approval to start a global

Phase III clinical trial for APL-1702 (Cevira).

The EP 2983780 patent covering the commercial Cevira device in Europe, will

expire 09 April 2034.

Notes to editors

About Cevira

Cevira® is a photodynamic drug-device combination product that is being

developed for non-surgical treatment of high-grade cervical dysplasia. Cevira®

is easily placed on the cervix by the gynecologist and removed by the patient,

with no disruption of normal daily activities. Only one or two treatments are

needed.

About Cervical dysplasia

High-grade cervical squamous intraepithelial lesions (HSIL) is a precancerous

condition caused by a persistent HPV infection, a highly prevalent sexually

transmitted disease resulting in approximately 10 million cases with high grade

disease and > 500 000 new cases of cervical cancer each year. In China, 1-2% of

women have HSIL each year. Currently, surgical excision is the most common

treatment option offered to women with cervical high-grade dysplasia. In women

of childbearing age in particular there is a high medical need for a non

-surgical option which preserves the cervical anatomy and function. No such

medical alternative is approved to date.

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA

For further information, please contact:

Photocure

Dan Schneider

President and CEO

Tel: +1-609 759-6515

Email: ds@photocure.com

Erik Dahl

CFO

Tel: +47 45055000

Email: ed@photocure.com

Media and IR enquiries:

Geir Bjørlo

Corporate Communications (Norway)

Tel: +47 91540000

Email: geir.bjorlo@corpcom.no